New agent improves kidney transplant survival in mice, likely to speed replacement of other organs

New research published online in the FASEB Journal details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs. OPN-305 works by preventing inflammation triggered by oxygen deprivation in the donated organ, allowing for better recovery after transplantation. Specifically, it binds to sensors on transplant tissue, called "toll-like receptors" or "TLR-2," in the circulating blood and turns off signals that provoke inflammation. In addition, the compound is likely to extend the life of a donated organ after it has been transplanted.

"Although the work was carried out with kidney transplants, it is likely that other types of transplants could benefit. Other common types of , needed for liver or heart or lung disease, are also vulnerable to damage induced by the transplant procedure, especially where there has been a long period of cold storage without a normal blood supply," said Steven H. Sacks, study author from the MRC Centre for Transplantation at King's College School of Medicine in London. "For other medical conditions such as stroke and heart attack, where the blood flow to vital organs is blocked, it is highly possible that this new treatment may also make recovery more complete."

Sacks and colleagues made this discovery using two groups of mice receiving kidney transplants. The first was treated with OPN-305 and the second was given an irrelevant agent. The group treated with the OPN-305 showed good recovery of function in the transplanted organ, whereas the control treatment had no effect and the animals developed severe organ damage. Researchers say a clinical trial design using a similar antibody for use in human patients is underway.

"This new antibody is exciting because it basically increases the 'shelf life' of organs that are critically needed for transplantation," said Gerald Weissmann, M.D., Editor-in-Chief of the . "Since it is directed against molecules that regulate inflammation, OPN-305 is likely to extend the lifespan of any other transplanted organs. Although human trials have not yet begun, this work identifies TLR's as targets for drugs to reduce inflammation and organ rejection."

Related Stories

Kidney transplants: Expanding the pool of available organs

date May 20, 2010

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

date 15 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

date Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.